{"id":"khk4083","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, KHK4083 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.","oneSentence":"KHK4083 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:15.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT06214481","phase":"PHASE1","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2024-01-23","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT06376045","phase":"PHASE2","title":"A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-05-24","conditions":"Asthma","enrollment":317},{"nctId":"NCT05633355","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-01-30","conditions":"Atopic Dermatitis","enrollment":187},{"nctId":"NCT05398445","phase":"PHASE3","title":"A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-05-31","conditions":"Atopic Dermatitis","enrollment":769},{"nctId":"NCT05724199","phase":"PHASE3","title":"A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-02-21","conditions":"Atopic Dermatitis","enrollment":746},{"nctId":"NCT05899816","phase":"PHASE3","title":"A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-06-07","conditions":"Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis","enrollment":221},{"nctId":"NCT05882877","phase":"PHASE3","title":"A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-05-31","conditions":"Atopic Dermatitis","enrollment":2621},{"nctId":"NCT05651711","phase":"PHASE3","title":"A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-12-14","conditions":"Atopic Dermatitis","enrollment":726},{"nctId":"NCT03703102","phase":"PHASE2","title":"Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2018-10-22","conditions":"Atopic Dermatitis","enrollment":274},{"nctId":"NCT02647866","phase":"PHASE2","title":"Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2016-06","conditions":"Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative","enrollment":66},{"nctId":"NCT02985593","phase":"PHASE1","title":"A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2016-12","conditions":"Healthy Men and Subjects With Ulcerative Colitis","enrollment":155},{"nctId":"NCT03096223","phase":"PHASE1","title":"A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2017-04-10","conditions":"Dermatitis, Atopic","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"KHK4083","genericName":"KHK4083","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KHK4083 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}